Drug Profile
Pegfilgrastim biosimilar - PharmaEssentia
Alternative Names: PEG-GCSF - PharmaEssentiaLatest Information Update: 28 Oct 2023
Price :
$50
*
At a glance
- Originator PharmaEssentia Corporation
- Class Antineoplastics; Chemoprotectants; Granulocyte colony-stimulating factors; Polyethylene glycols; Recombinant proteins
- Mechanism of Action Granulocyte colony stimulating factor receptor agonists; Granulocyte colony-stimulating factor replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Neutropenia
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for preclinical development in Neutropenia in Taiwan (Parenteral)
- 19 Sep 2019 Preclinical trials in Neutropenia in Taiwan (Parenteral) (Pharmaessentia pipeline September 2019)
- 19 Sep 2019 PharmaEssentia plans to submit an IND application with the regulatory body worldwide (exc USA) for Neutropenia (PharmaEssentia pipeline September 2019)